IP Library Granted Patent US 7,270,826
Granted Patent B2
US 7,270,826 · App. 11/028,600 · Granted Sep 18, 2007

Methods of using

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,270,826
App. No.
11/028,600
Granted
Sep 18, 2007
Kind
B2
Abstract

The present invention uses pharmaceutical preparations of Botulinum toxin to induce neurogenic atrophy to alter muscle volume and subsequently, facial contour. Reduction in lip volume is accomplished using the disclosed methods thereby producing a favorable effect on a hypervolemic lip deformity. In other embodiments of the invention, the methods disclosed herein may be used to shrink muscle bulk and contour, especially in the face. In one embodiment, treating excessive muscle bulk below the eyelids can cause a smoothing of the lower lid and cheek contour producing a favorable improvement in appearance. Such an application is in distinct contrast to rhytide (wrinkle reduction) as the injected region does not contain wrinkles or any other form of dynamic line, merely excessive tissue bulk.

Claims (8)

1. A method for reducing lip volume in a subject in need of reduced lip volume, comprising the steps of: assessing lip volume, administering a therapeutically effective amount of a pharmaceutical preparation of Botulinum toxin to one or both of the lips of said subject to thereby induce reduced lip volume in one or both of the upper and lower lips of said subject, and assessing lip volume after said administration.

2. The method of claim 1 , wherein said pharmaceutical preparation is administered to the orbicularis oris muscle of said subject.

3. The method of claim 1 , wherein said pharmaceutical preparation is administered to the lip retractors.

4. The method of claim 1 , wherein said subject has a hypervolemic lip deformity.

5. The method of claim 1 , wherein the pharmaceutical preparation of Botulinum toxin comprises any combination of more than one of immunotypes A, B, C, D, B, F and G.

6. The method of claim 1 , wherein about 5 to about 2000 Lethal Dose 50 (LD 50 ) units of Botulinum toxin are administered to said subject.

7. The method of claim 1 , wherein the pharmaceutical preparation of Botulinum toxin is administered via transcutaneous or transmucosal injection.

8. The method of claim 1 , wherein the pharmaceutical preparation of Botulinum toxin is administered via multifocal injection.

Assignments (7)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2016
From: BORODIC, GARY E, DR
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 038249/0590 →